HMN-176 is a potential new cancer therapeutic known to retard the proliferation of tumor cell lines. Here, we show that this compound inhibits meiotic spindle assembly in surf clam oocytes and delays satisfaction of the spindle assembly checkpoint in human somatic cells by inducing the formation of short and/or multipolar spindles. HMN-176 does not affect centrosome assembly, nuclear envelope breakdown, or other aspects of meiotic or mitotic progression, nor does it affect the kinetics of Spisula or mammalian microtubule (MT) assembly in vitro. Notably, HMN-176 inhibits the formation of centrosome-nucleated MTs (i.e., asters) in Spisula oocytes and oocyte extracts, as well as from isolated Spisula or mammalian centrosomes in vitro. Together, these results reveal that HMN-176 is a first-in-class anticentrosome drug that inhibits proliferation, at least in part, by disrupting centrosomemediated MT assembly during mitosis. [Mol Cancer Ther 2009;8(3):592 -601] 
Introduction

HMN-176 ((E)-4-{[2-N-
amino] stilbazole} 1-oxide) is a newly synthesized sulfonamide derivative that exhibits potent antiproliferative activity in human tumor cell lines, especially breast, non -small cell lung, and ovarian tumors (1) . The drug is also cytotoxic to drug-resistant human and murine cell lines (2) . When Adriamycin-resistant human ovarian cancer cells (K2/ARS) are exposed to HMN-176, the expression of the multidrug resistance gene MDR1 is down-regulated, apparently due to the ability of HMN-176 to prevent NF-Y transcription factor binding to the MDR1 promoter (3) . Additional evidence that HMN-176 inhibits cell proliferation, in part, via its effects on transcriptional regulation is suggested from cDNA microarray analyses of human ovarian carcinoma lines, in which the drug is reported to upregulate or down-regulate expression of several genes (1) . Phase I clinical trials of HMN-214, the prodrug form of HMN-176, have been completed in patients with solid tumors. Tumor stabilization and decrease in serum tumor markers were shown in select patients (4) . HMN-214 is currently being pursued in phase II and III studies.
Flow cytometric studies on growing HeLa cell cultures reveal that HMN-176 treatment leads to an accumulation of G 2 -M cells, suggesting that its antiproliferative effects may be related to inhibition of mitosis, resulting in apoptosis (1 -3) . However, it is not clear from these studies whether HMN-176 disrupts progression through mitosis (i.e., spindle assembly and chromosome segregation) via its upstream effects on transcription or more directly by targeting spindle components, or perhaps both. To resolve this issue, we directly examined the effects of HMN-176 on spindle assembly during mitosis and meiosis using Spisula solidissima (Atlantic surf clam) oocytes.
The Spisula oocyte system offers several advantages for the identification of agents that inhibit cell cycle progression (5, 6) . First, the organisms are commercially fished off the northeast coast of the United States, and oocytes are easily obtained in large quantities. This offers virtually unlimited quantities of identical cells arrested at the same phase of the cell cycle, G 2 -M of meiosis I. Second, oocytes are 55 Am in diameter and sufficiently transparent to allow direct observations of processes resulting in spindle assembly and chromosome segregation with common polarized light and immunofluorescence microscopy. Third, oocytes are easily activated either by fertilization or by exposure to KCl. Once activated, oocytes proceed synchronously through meiosis, completing nuclear envelope breakdown and spindle assembly within 15 minutes. Based on these unique properties, the Spisula oocyte model offers a rapid live cell assay system for the identification of drugs that affect spindle assembly and function in animal cells.
Materials and Methods
In vivo Assembly of Spindles in Spisula Oocytes Mature S. solidissima oocytes were obtained from the Marine Resource Center of the Marine Biological Laboratory (Woods Hole, MA). Females were selected, gonadal tissue was dissected, and oocytes were harvested as previously described (5, 6) .
For time-lapse video microscopy, a 10% v/v suspension of oocytes was prepared in filtered seawater. HMN-176 (Nippon Shinyaku Co. Ltd.) dissolved in DMSO was added to a final concentration of 0.25 Amol/L and incubated for 10 min at ambient temperature, and oocytes were activated with 0.07 mol/L KCl (7). The KCl stock was supplemented with HMN-176 or DMSO to maintain appropriate concentrations in the final suspension. Oocyte suspensions were mounted on glass slides and examined using a Zeiss Axiophot polarized light microscope equipped with a 20Â/0.50 numerical aperture objective lens and a Hamamatsu SIT video camera coupled to MetaMorph image processing software (Universal Imaging Corp.).
For immunofluorescence studies, aliquots of oocyte suspensions were removed at various time points (0, 4, 8, 16, 25, 35 , and 45 min after activation), transferred to fixation solution [0.6% Brij-58, 4% formaldehyde, 100 mmol/L PIPES, 5 mmol/L EGTA, 1 mmol/L MgCl 2 (pH 6.8) with NaOH] for at least 15 min, washed in PBS, and blocked with 3% bovine serum albumin in PBS as described (8) . To visualize mammalian microtubules (MT), oocytes were labeled with a primary rat antibody to a-tubulin (Serotec), washed in PBS, and then labeled with a secondary antirat antibody conjugated to Alexa Fluor 488 (Invitrogen). Hoechst 33342 (1 Ag/mL) was added to one of the final wash steps to visualize chromosomes. Oocytes were observed with a Zeiss Axioimager Z1 system equipped with a 40Â/1.3 numerical aperture objective coupled to Axiovision software (Zeiss).
Centrosome MT Nucleation Assays Aster Formation in Cell Extracts. Four-minute activated (A4 ¶) Spisula oocyte extract was prepared (9) , snap frozen in liquid nitrogen, and stored at À80jC. To assay for aster assembly, extract was thawed and treated with HMN-176 (final concentration of 2.5, 0.25, or 0.025 Amol/L) or DMSO alone and kept on ice for 10 min. Samples were warmed to room temperature for 20 min to induce aster assembly, fixed, and processed for immunofluorescence microscopy as previously described (7) . MTs were labeled with a primary rat antibody to a-tubulin and a secondary antirat antibody conjugated to Alexa Fluor 488. Centrosomes were labeled with a primary mouse antibody to g-tubulin (Sigma) and a secondary antimouse antibody conjugated to Texas red (Jackson ImmunoResearch). A Zeiss Axiophot epifluorescence microscope equipped with a 63Â/1.3 numerical aperture objective lens and a Hamamatsu SIT video camera coupled to MetaMorph processing software were used for imaging.
Aster Formation in Defined Medium. Aster assembly was assayed in defined medium using isolated human and Spisula centrosomes combined with isolated tubulin. Spisula centrosomes were purified from A4 ¶ extract by centrifugation through a sucrose step gradient (6, 10) . Three-cycled Spisula tubulin (3Â tubulin) was isolated from activated extracts by three cycles of MT polymerization and depolymerization (6, 10 -12) . Centrosomes were incubated with 3Â tubulin (0.55 mg/mL) containing dilutions of HMN-176 (2.5, 0.25, and 0.025 Amol/L) or DMSO alone for 20 min at 24jC to assemble asters. Samples were fixed and processed for immunofluorescence microscopy as described.
For assays on human centrosomes, isolated HeLa S3 centrosomes (kind gift of Dr. Jeffrey Parvin, Department of Pathology, Brigham and Women's Hospital, Boston MA; ref. 13) were challenged with 2 mg/mL bovine brain tubulin containing HMN-176 (2.5, 0.25, or 0.025 Amol/L) or DMSO alone and incubated at 37jC for 20 min. Samples were fixed and processed for immunofluorescence microscopy as described.
Recovery of MT Nucleation Potential in Potassium Iodide^Insoluble Centromatrix Remnants
Potassium iodide -insoluble centromatrix remnants (KICR) were created from isolated Spisula centrosomes and immobilized on glass coverslips (14, 15) . The effect of HMN-176 on recovery of MT nucleation potential was tested in two ways. In the first assay, KICRs were treated with centrosome-free high-speed extract containing 2.5 Amol/L HMN-176, washed with PBS, and then challenged with 0.55 mg/mL 3Â Spisula tubulin. In the second assay, KICRs were reconstituted with untreated centrosome-free high-speed extract, washed, and then challenged with 0.55 mg/mL 3Â Spisula tubulin containing 0.025, 0.25, or 2.5 Amol/L HMN-176. Samples were fixed and processed for immunofluorescence microscopy as described.
Tubulin Polymerization
The effect of HMN-176 on MT assembly in the absence of centrosomes was tested using Spisula tubulin and bovine brain tubulin. 3Â and 5Â (glutamate purified) Spisula MT protein was isolated as previously described (6, 12, 15) . Spisula tubulin was adjusted to a final concentration of 0.55 mg/mL; supplemented with either HMN-176 (2.5, 0.25, or 0.025 Amol/L), 2.5 Amol/L colchicine, or DMSO; incubated on ice for 10 min; and then warmed to room temperature to induce polymerization. Turbidity was measured as a function of absorbance at 350 nm (12, 16) using a Shimadzu UV-1650 UV-Visible spectrophotometer to assay MT assembly.
Polymerization assays were also done using 99% pure bovine brain tubulin (Cytoskeleton, Inc.) at a concentration of 3 mg/mL supplemented with 10% glycerol, 1 mmol/L GTP, and 1 mmol/L MgCl 2 . Samples were pretreated with the same concentrations of DMSO, HMN-176, and colchicine as the Spisula samples for 10 min, and turbidity measurements were made at 37jC and 340 nm. At the final time points of the turbidity assays, samples were removed to verify the presence of MTs. Samples were fixed (at 24jC for Spisula and 37jC for bovine) with 1% glutaraldehyde in PBS and then processed for immunofluorescence as described.
Mitosis in Cultured Human Cells Human CFPAC-1 (a pancreatic adenocarcinoma line) and hTERT-RPE1 (telomerase immortalized retinal pigment epithelial cells) cells were cultured on coverslips as previously described (17) . Coverslips were assembled into Rose chambers (18), treated with either 2.5 Amol/L HMN-176 or DMSO alone, and incubated at 37jC for 2 h. The chambers were then loaded to a Nikon Diaphot microscope with a stage temperature of 37jC. Using a 20Â phase-contrast objective lens, cells were filmed by time-lapse video microscopy and the duration of mitosis for individual cells was measured using Image-Pro Plus software (Media Cybernetics).
For immunofluorescence studies, cells cultured on coverslips were fixed and labeled as previously described (17) . MTs were labeled using a primary mouse antibody to h-tubulin (Sigma) and a secondary antimouse antibody conjugated to Alexa Fluor 546 (Invitrogen). Chromosomes were visualized by adding 1 Ag/mL Hoechst 33342 to one of the wash steps. Cells were imaged on a Nikon Diaphot epifluorescence microscope equipped with a 60Â/1.4 numerical aperture objective lens and SPOT camera. Spindle interpolar distances were measured using ImagePro Plus software.
Results
HMN-176 Delays Satisfaction of the Spindle Assembly Checkpoint in Cultured Human Cells
Based on indirect flow cytometric data, previous reports indicate that HMN-176 arrests cells at the G 2 -M phase of the cell cycle, which suggests that they are delayed in mitosis (1 -3). We therefore investigated how HMN-176 affects progression through mitosis in cultures of RPE1 and CFPAC-1 cells treated with 2.5 Amol/L HMN-176 for 2 hours before initiating time-lapse video light microscopy observations. The doubling times of these cell lines are comparable, ranging from 30 to 32 hours for CFPAC-1 cells (19) and 28 to 33 hours for RPE1 cells. 4 For this study, we defined the duration of mitosis as the period between nuclear envelope breakdown and chromatid disjunction at anaphase onset. As summarized in Table 1 , HMN-176 greatly increased the duration of mitosis in both cell lines. This delay in satisfying the spindle assembly checkpoint indicates that HMN-176 negatively affects some aspects of spindle MT assembly and/or behavior.
To determine how HMN-176 delays satisfaction of the spindle assembly checkpoint, we examined the structure of spindles formed in RPE1 and CFPAC-1 cultures treated for 2 hours with either 2.5 Amol/L HMN-176 or 0.01% DMSO before fixation and indirect immunofluorescence labeling for h-tubulin (Fig. 1) . In DMSO-treated cultures, bipolar spindles were observed in f90% of the mitotic cells in both cell lines and their pole-pole length (i.e., the centrosometo-centrosome distance) averaged 9.6 Am ( Table 2) , which is typical for human cells. By contrast, in both cell lines, spindles formed in the presence of HMN-176 were significantly shorter (P V 0.05) than those in control cultures (Table 2) . Furthermore, although the drug did not significantly affect the percentage of bipolar spindles formed in RPE1 cultures (91% versus 87%), it decreased the number of bipolar spindles (88% to 16%) while increasing the number of multipolar spindles (from 10% to 84%) in CFPAC-1 cultures (Table 2 ). In this context, it is noteworthy that, relative to RPE1 cells, HMN-176 had significantly less effect on reducing the length of CFPAC-1 spindles. Overall, the effect of HMN-176 on spindle morphology did not seem to be related to effects on microtubule polymerization, as had been confirmed in other studies (2) .
HMN-176 Inhibits Spindle Assembly in Spisula Oocytes
The S. solidissima (Atlantic surf clam) oocyte has been used extensively to study the role of cyclin (20, 21) and ubiquitin (22) in cell cycle progression as well as how centrosome maturation and spindle assembly are regulated during meiosis (7, 23) . Although these proteins have been implicated in human cancers, there have been no direct comparisons of sequence and structure between Spisula and human mitotic proteins. However, studies have shown conservation of centrosome proteins among invertebrate and vertebrate species. Further, functional hybrid centrosomes have been reconstituted using a Spisula centromatrix combined with components present in Drosophila, Xenopus, and CHO cell extracts (24) .
The Spisula oocyte is arrested in late prophase of meiosis I, when centrosomes and centrioles are not present (7). After fertilization or activation, oocytes rapidly assemble two centrosomes each containing one centriole. Nuclear envelope breakdown occurs 8 minutes after activation, and during the next 7 minutes, the oocyte forms a bipolar meiosis I spindle containing two centrosomes, each with two centrioles (7) . Cytoplasmic oocyte extracts faithfully execute all of these events in vitro (6), and functional centrosomes that retain the ability to organize MT arrays in vitro can be isolated in bulk (10) . Because Spisula oocytes contain all components necessary to assemble a functional spindle in the absence of transcription or translation (21) , it remains an excellent system for examining how a drug affects spindle assembly and function without potential upstream complications resulting from RNA and protein synthesis.
To determine how HMN-176 affects spindle assembly in vivo, Spisula oocytes were pretreated for 10 minutes with 0.25 Amol/L HMN-176 in 0.001% DMSO or 0.001% DMSO alone. Oocytes were activated to complete meiosis and observed by time-lapse video polarized light microscopy. When oocytes were treated with DMSO, germinal vesicle 4 Dr. Choy-Pik Chiu, Geron Corp., unpublished data. breakdown, aster formation, and spindle assembly all occurred at the appropriate times during meiosis I ( Fig. 2A) . In contrast, oocytes treated with HMN-176 underwent germinal vesicle breakdown, but asters or spindles failed to form, even after prolonged periods.
To confirm this, oocytes were treated with HMN-176 or DMSO, activated, and fixed at various time points for immunofluorescence microscopy. DMSO-treated oocytes progressed normally through meiosis, each extruding two polar bodies by 45 minutes (Fig. 2B ). Oocytes treated with HMN-176 assembled tubulin-staining centrosomes by the expected 4-minute time point, but no asters were detected even 45 minutes after oocyte activation. By 45 minutes after activation, the two centrosomes split to produce four foci. However, aster formation, spindle assembly, and polar body extrusion were completely inhibited in HMN-176 -treated cells. Together, these data suggest that HMN-176 prevents spindle assembly and meiosis in Spisula oocytes by inhibiting centrosome-dependent MT nucleation (i.e., aster formation).
HMN-176 Inhibits Aster Formation In vitro
To further investigate how HMN-176 affects centrosomedependent aster formation, we conducted in vitro experiments on cytoplasmic extracts prepared from A4 ¶ Spisula oocytes. Extracts pretreated with HMN-176 (2.5, 0.25, and 0.025 Amol/L) or DMSO (0.01, 0.001, and 0.0001%) were warmed to 24jC, inducing aster formation. In extracts treated only with DMSO, centrosomes rapidly nucleated astral MT arrays similar in size to asters in untreated extracts (Fig. 3A) . However, HMN-176 inhibited aster formation in a concentration-dependent manner. No effects on aster formation were detected at 0.025 Amol/L, whereas aster size was noticeably reduced at 0.25 Amol/L HMN-176. HMN-176 (2.5 Amol/L) completed inhibited centrosome-dependent aster formation.
Next, we examined how HMN-176 affects aster formation in defined medium containing isolated centrosomes and purified tubulin. Centrosomes purified from A4 ¶ extracts were challenged with 3Â Spisula tubulin containing HMN-176 (2.5, 0.25, and 0.025 Amol/L) or DMSO (0.01, 0.001, and 0.0001%) and warmed to 24jC to induce aster formation. DMSO had no effect on centrosome-dependent aster formation (Fig. 3B) . However, unlike observations in A4 ¶ extract, even the lowest tested concentration of HMN-176 (0.025 Amol/L) decreased aster size, which was further reduced in 0.25 Amol/L HMN-176, until it was To determine if HMN-176 also inhibits aster MT formation from human centrosomes, isolated HeLa centrosomes were challenged with bovine brain tubulin containing HMN-176 (0.025, 0.25, or 2.5 Amol/L) or DMSO alone (0.0001, 0.001, or 0.01%; Fig. 4A ). Asters formed from centrosomes challenged with DMSO-treated tubulin were comparable in size with the asters in samples with untreated tubulin. At the two lowest concentrations, HMN-176 did not affect aster size, but at 2.5 Amol/L, aster assembly was blocked. Although differential sensitivity to the drug between Spisula and human centrosomes is possible, clearly HMN-176 inhibits centrosome-dependent MT assembly and aster formation in both vertebrate and invertebrate centrosomes.
HMN-176 Does Not Inhibit Centrosome Assembly In vitro
We asked if HMN-176 affects the recruitment of g-tubulin ring complexes (g-TURC), required for centrosomemediated MT nucleation (14) , to the centrosome. Treating isolated Spisula centrosomes with potassium iodide removes g-TURCs, leaving an insoluble centrosome matrix (KICR) that can bind g-TURCs and recover the ability to nucleate MTs when incubated in animal cell extracts (24) . To determine if HMN-176 inhibits restoration of centrosome MT nucleation potential, we observed the effect of HMN-176 on the binding of g-TURCs to the centromatrix, an integral step in centrosome assembly. KICRs were treated with HMN-176, parthenogenetically activated, and filmed by time-lapse video microscopy. The DMSO-treated oocytes (a -c ) progressed through meiosis I. The germinal vesicles present at 0.5 min were broken down by 9 min, at which time bipolar spindles were seen (arrows, b ). By 26 min, spindles had migrated in preparation for cytokinesis (arrows, c). In oocytes treated with HMN-176 (d -f ), the envelope of the germinal vesicle became less distinct at 9 min (e). f, breakdown was complete by 26 min but no asters or spindles were formed. Time-lapse videos are available online as Supplementary Data. 5 Bar, 20 Am.
B, Spisula oocytes were treated with 0.001% DMSO or 0.25 Amol/L HMN-176, activated, fixed, and immunostained for a-tubulin (green ) and nucleic acid (blue ) at various time points. The oocytes treated with DMSO (a -d ) followed the normal progression of meiosis. A pair of asters formed within 4 min (b ) and an early meiotic spindle assembled by 8 min (c ). By 45 min, two polar bodies were visible (arrows, d ). In the oocytes treated with HMN-176 (e -h ), two small foci of a-tubulin are detectable at 4 min (f), indicating centrosome assembly. However, these asters remained small and did not organize the chromosomes into a meiotic spindle (g ). By 45 min, centrosomes had duplicated to give four (arrows, h ) but, still, did not form spindles or organize the chromosomes. Bar, 20 Am. 5 Supplementary material for this article is available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/).
Spisula extracts containing either 2.5 Amol/L HMN-176 or 0.01% DMSO, washed, and then challenged with 3Â Spisula tubulin. Neither HMN-176 nor DMSO inhibited the recovery of MT nucleating potential, and the asters assembled were similar in size to those of untreated controls (Fig. 4B) . Thus, it is likely that HMN-176 has no effect on centrosome assembly but rather inhibits the nucleation of MTs by centrosomes after the centrosome is assembled.
HMN-176 Does Not Disrupt MT Polymerization
The results from in vivo and in vitro experiments suggest that HMN-176 inhibits centrosome-dependent MT nucleation. It remains possible, however, that the drug prevents aster assembly by disrupting tubulin polymerization itself. We therefore asked how HMN-176 affects the polymerization of Spisula and mammalian tubulin using standard MT polymerization assays based on turbidity (16) and immunofluorescence microscopy. Samples of 3Â and 5Â Spisula tubulin were pretreated with HMN-176 (0.025, 0.25, and 2.5 Amol/L), 0.01% DMSO, or 2.5 Amol/L colchicine, a known inhibitor of MT polymerization (25) . Tubulin polymerization was then monitored by turbidity measurements. As expected, samples treated with colchicine initially assembled a small amount of polymer, which then rapidly depolymerized (Fig. 5A) . All other samples (untreated, DMSO treated, and HMN-176 treated) displayed a relatively standard curve for MT polymerization. Similarly, the purified 5Â tubulin samples showed unremarkable tubulin polymerization kinetics even in the presence of HMN-176. With the exception of colchicine treatment, all samples were comparable in their rates of polymerization and final measures of turbidity. To verify that the turbidity increases were due to MT assembly, samples were taken from the 5Â tubulin polymerization assays and examined by immunofluorescence microscopy (Fig. 5B) . With the exception of colchicine treatment, normal MTs were found in all other samples. Thus, although HMN-176 may have subtle effects on the initial polymerization rate during the log phase, based on the turbidity measurements, the drug had little effect on MT polymerization.
Similar polymerization assays were conducted using 3 mg/mL mammalian tubulin. Tubulin samples were pretreated with the same concentrations of DMSO, HMN-176, or colchicine as above and warmed to 37jC for turbidity measurements. Samples treated with colchicine formed a small amount of polymer (Fig. 5C) , whereas all other samples, including those treated with HMN-176, displayed normal tubulin polymerization (26) . MTs from the plateau phase were observed by immunofluorescence in all samples that showed an increase in turbidity, including those treated with HMN-176 but excluding ones treated with colchicine (Fig. 5D) . Collectively, these studies reveal that HMN-176 does not adversely effect the polymerization of vertebrate or invertebrate tubulin into MTs.
Discussion
Centrosomes are the major MT organizing centers in animal cells. These organelles play an important role in cell division by contributing to the assembly of bipolar spindles that assure the proper segregation of chromosomes. Therefore, it has long been thought that centrosome defects could contribute to missegregation of chromosomes and genetic instability, thereby contributing to malignancy (27, 28) . Importantly, the MTs, which are organized by centrosomes, have been useful targets for the development of cancer therapeutics. Drugs such as paclitaxel and vincristine, among others, have proven to be useful as chemotherapy. Because MTs are useful targets for the development of anticancer drugs, it follows that the centrosome, which organizes MTs, could be an alternative target for the development of therapeutic agents.
We have developed a series of unique and rapid live cell and in vitro assays to identify small organic compounds that affect spindle assembly. This approach is based on initial screening using the S. solidissima oocyte model system followed by further analysis of the effects of these lead compounds on mammalian cultured cells. The Spisula oocyte system offers several advantages for the identification of agents that inhibit cell cycle progression (29) . The uniform arrest of the oocytes at G 2 -M and synchronous progression through meiosis I following activation allows for standardized in vivo observation. Furthermore, we have developed a series of in vitro assays using oocyte extracts, purified centrosomes, and tubulin for the rapid assessment of whether drugs affect centrosome function directly, removing consideration of upstream or downstream drug effects.
Using the Spisula model system, we identified HMN-176 as a drug that disrupts spindle assembly. HMN-176 is a novel antimitotic compound that displays a unique ability to inhibit cell cycle progression (1 -3). We tested the effect of HMN-176 on meiotic and mitotic cell cycle progression and found that it changes spindle assembly in both vertebrates and invertebrates. We have shown that although HMN-176 inhibits spindle assembly in Spisula oocytes, all other aspects of the meiotic cell cycle, including nuclear envelope (germinal vesicle) breakdown and centrosome splitting, occurred normally within expected time frames. Most importantly, we have shown, for the first time, that HMN-176 inhibits centrosome-dependent MT nucleation and aster formation in live cells and in vitro using a variety of cell-free assays. Finally, we have shown that this drug has little or no effect on invertebrate and mammalian MT polymerization. Based on these studies, we propose that HMN-176 is a first-in-class anticentrosome drug that inhibits centrosome-dependent MT nucleation.
Although the Spisula oocyte system and its related assays are useful as an initial drug screening tool, the action of HMN-176 was also characterized using human cells and centrosomes. HMN-176 inhibited the ability of purified HeLa S3 centrosomes to nucleate and organize bovine tubulin into astral arrays but had little effect on bovine MT polymerization. Furthermore, MT polymerization was not inhibited in live cells because MTs were clearly observed in HMN-176 -treated human cell lines in both this study and others (2) . Although HMN-176 treatment of both a noncancerous line (RPE1) and a cancerous line (CFPAC-1) resulted in a significant delay in mitosis, MTs were observed in all cells. However, a differential effect was observed when comparing the phenotypes of these cell lines. In RPE1 cells, HMN-176 did not dramatically alter mitotic cell morphology because these cells formed bipolar spindles. However, the interpolar distance of spindles assembled in HMN-176 -treated RPE1 cells was approximately half the distance found in control cells. Therefore, the major effect of HMN-176 on RPE1 cells was to delay mitosis and reduce spindle length. In transformed CFPAC-1 cells, the results were more remarkable. Similar to RPE1 cells, HMN-176 treatment resulted in a delay in mitosis, but the delay was notably longer (three times versus five times normal time in mitosis). Most importantly, HMN-176 treatment induced multipolar spindle assembly in CFPAC-1 cells. The appearance of multipolar spindles could be the result of amplification of centrosome numbers or the result of chromosome-directed MT assembly in the absence of normal centrosome function.
We propose the following model to explain the action of HMN-176 on human cells. By significantly decreasing the centrosome contribution to spindle assembly, the drug forces RPE1 and CFPAC-1 to form spindles predominantly via the chromosome-directed assembly route. In the absence of centrosome function, mammalian cells are known to have a very strong chromosome-directed spindle assembly component (30) . This also explains the observed radical difference between how the drug affects spindle formation in Spisula oocytes and human somatic cells.
Chromosome-directed spindle assembly does not occur in marine organisms (31), a mechanism that holds true in Spisula meiotic extracts. 6 This same reasoning also explains the observed difference in spindle assembly between immortalized (RPE1) and cancer (CFPAC-1) cells: relative to noncancerous human RPE1 cells, the chromosomedirected route is down-regulated in cancer (HeLa) cells, meaning, that they rely much more on their centrosome function to achieve mitosis. 7 The enhanced multipolar colchicine formed a small amount of polymer, which quickly diminished to initial levels and thereafter remained depolymerized. B, samples were taken at the end of the polymerization assay using 5Â Spisula tubulin, fixed, and immunostained for a-tubulin. The increased turbidity in the untreated sample and those treated with DMSO and HMN-176 was due to the formation of microtubules. The tubulin treated with colchicine formed amorphous aggregates. C, 3 mg/mL bovine tubulin was assayed for polymerization in the presence of DMSO, HMN-176, and colchicine. All tubulin treatments, except colchicine, showed a rapid increase in turbidity and similar plateaus, with no clear effect of HMN-176 evident. Tubulin treated with colchicine formed only a small amount of polymer. D, samples were taken at the end of the polymerization assay using bovine tubulin, fixed, and immunostained for a-tubulin. spindle phenotype in CFPAC-1 in response to HMN-176 may be due to the fact that, in lieu of strong asters, a chromosome-based route to spindle assembly is active, resulting in the assembly of predominantly multipolar spindles in these cultured cells. Given the results of the studies described, we propose that in CFPAC-1 cells, centrosome MT nucleation is inhibited and thus the chromosome-directed spindle assembly mechanism continues to function yielding abnormal spindle assembly. It may be that centrosomes of nontransformed cells, such as RPE1, are either more resistant to drug effects or that these cells are more capable of driving organized bipolar spindle assembly in the presence of compromised centrosome function than are transformed cells.
Recent research has shed light on a unique secondary mechanism of cell cycle arrest for the microtubule inhibitor paclitaxel. Standard concentrations cause mitotic arrest of cells, but lesser concentrations allow progression through mitosis (albeit delayed) and cause subsequent interphase arrest, in which the cells neither proliferate nor undergo apoptosis (32) . It is uncertain if the effect of paclitaxel on tubulin kinetics is related to this phenomenon. An accumulation of cellular p53 during prolonged mitosis is proposed to cause the subsequent arrest. By a similar mechanism, differential sensitivity to HMN-176 could contribute to the prolongation of mitosis and accumulation of p53 as well as inhibition of centrosome function.
Regardless of the differing response to HMN-176 observed in human cultured cells, we propose that HMN-176 inhibits centrosome-dependent MT assembly, thereby inhibiting normal progression through the mitotic phase of the cell cycle and ultimately leading to cell death. The exact mechanism of drug inhibition of centrosome MT nucleation remains to be explored. As previously mentioned, initial studies of HMN-176 proposed that it may act as a transcriptional regulator, and indeed, the drug has been shown to affect gene expression (1, 3) . However, inhibition of protein expression in the Spisula system does not affect de novo meiotic spindle assembly (20, 33) . Thus, a second mechanism of drug action likely involves the inhibition of MT nucleation template structures, g-TURCs, present throughout centrosomes that are required for proper MT nucleation (14, 34) . Regardless of the exact mechanism of action, the studies presented provide strong evidence that the centrosome is a potential target for the development of cancer therapeutics.
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